Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iclepertin - Boehringer Ingelheim

Next Previous
Drug Profile

Iclepertin - Boehringer Ingelheim

Alternative Names: BI-425809

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antipsychotics; Aza compounds; Fluorine compounds; Heterocyclic bicyclo compounds; Isoxazoles; Nootropics; Small molecules; Sulfones
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase II Cognition disorders

Most Recent Events

  • 11 Mar 2025 Boehringer Ingelheim completes the phase III CONNEX-X trial in Schizophrenia in Hungary, Austria, Australia, Argentina, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Japan, South Korea, Lithuania, Malaysia, Mexico, New Zealand, the Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Taiwan, UK and USA(PO) (NCT05211947) (EudraCT2020-003745-11)
  • 17 Nov 2024 Boehringer Ingelheim completes phase III CONNEX-2 trial in Schizophrenia in Argentina, Brazil, Chile, Croatia, France, Japan, Malaysia, the Netherlands, Poland, Romania, Serbia, Slovakia, Spain, Ukraine and USA (NCT04846881)
  • 28 Oct 2024 Boehringer Ingelheim completes the phase III CONNEX-3 trial in Schizophrenia in USA, Argentina, Austria, Belgium, Brazil, Bulgaria, China, Finland, South Korea, Lithuania, Mexico, Portugal, Serbia, Taiwan, the UK, Czech Republic, Germany and Denmark (NCT04860830) (EUCT2020-003726-23)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top